Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs VRDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRDN Captures Overall Composite Edge (36.8 SELL vs 35.5 SELL), While MESO Leads 3–2 on Growth & Valuation Pillars

VRDN Overall Winner 6-Pillar Tally: MESO 3 – 2 VRDN (1 Tie) Matrix Metrics: MESO 3 – 7 VRDN

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. MESO trades at $12.47 (N/M Forward P/E, -42.6% operating margin) versus VRDN at $30.22 (1.0x Forward P/E, -1781.4% operating margin).

  • Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both MESO (35.5/100 SELL) and VRDN (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3); meanwhile VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs VRDN
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22
VRDN NASDAQ Head-to-Head Winner
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$30.22
-2.1% 1D
Market Cap $3.5B
TTM Revenue $26M
Forward P/E 1.0x
Beta / 30D Vol 1.12β · 64% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 72
RSI-14: 72.2 · SMA20: $26.61 · SMA50: $22.89

6-Pillar Scorecard Institutional Category Breakdown (MESO 3 – 2 VRDN)

Columns: Metric · MESO · VRDN
1. Valuation Multiples VRDN
Forward P/E N/M 1.0x
Trailing P/E N/M 1.0x
PEG Ratio N/M N/M
EV / Revenue 14.1x 134.2x
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% -63.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M $26M
Market Cap $1.7B $3.5B
3. Profitability & Quality MESO
Gross Margin 80.0% N/A
Operating Margin -42.6% -1781.4%
Net Profit Margin -47.8% 0.0%
Return on Equity (ROE) -9.9% -83.7%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$353M
Cash Flow Margin -37.1% EBITDA Mgn N/A
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $70M Net Debt (0.42x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRDN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 76.8% (37th %ile) 87.7% (20th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (3) vs VRDN (7)
Institutional Metric MESO VRDN Criterion Row Edge
Market Capitalization
Scale
$1.7B $3.5B Larger Scale VRDN
Trailing P/E Ratio
Valuation
N/M 1.0x Lower Multiple VRDN
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple VRDN
Revenue Growth (YoY)
Growth
+390.7% -63.5% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -1781.4% Higher Margin MESO
Net Profit Margin
Profitability
-47.8% 0.0% Higher Margin VRDN
Return on Equity (ROE)
Capital Efficiency
-9.9% -83.7% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 81% ($13–$34) Stronger Trend VRDN
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.12β · 64% Vol Lower Realized Risk VRDN
Unified Institutional Score
Composite Signal
35.5 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite VRDN
Trailing 12M Revenue (USD)
Operating Scale
$120M $26M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · 134.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$353M ($70M Net Debt (0.42x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VRDN +64.92 pp
MESO: -6.1% · VRDN: +58.82%
3M Horizon VRDN +51.49 pp
MESO: -25.19% · VRDN: +26.3%
6M Horizon VRDN +102.54 pp
MESO: -14.82% · VRDN: +87.72%
1Y Horizon VRDN +22.5 pp
MESO: -16.42% · VRDN: +6.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs VRDN. Trailing 12-month operating profitability (MESO -42.6% vs VRDN -1781.4%) and valuation multiples (MESO N/M vs VRDN 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
VRDN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross MarginN/A
Op. Margin-1781.4%
ROE / Fwd P/E-83.7% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRDN SURGE
5d in phase · OBV ACCUMULATION
Current IV 87.7%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRDN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -1781.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs VRDN Key Questions & Quantitative Answers

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. MESO trades at $12.47 (N/M Forward P/E, -42.6% operating margin) versus VRDN at $30.22 (1.0x Forward P/E, -1781.4% operating margin). Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both MESO (35.5/100 SELL) and VRDN (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3); meanwhile VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with VRDN at -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $26M for VRDN. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRDN.

VRDN screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus VRDN (-83.7% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.12β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.